Skip to main
TLX

TLX Stock Forecast & Price Target

TLX Analyst Ratings

Based on 4 analyst ratings
Strong Buy
Strong Buy 75%
Buy 25%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Telix Pharmaceuticals is well-positioned for future growth, with a strong pipeline of potential radiopharmaceuticals, as well as its current revenue from US sales of Illuccix. The recent collaboration agreement with Regeneron Pharmaceuticals not only provides significant upfront payments but also validates Telix's R&D platform and manufacturing capabilities, further strengthening its growth potential. Risks to the company's success include potential clinical and regulatory failures, which could impact sales estimates and hinder future growth.

Bears say

Telix Pharmaceuticals is currently highly dependent on the success of its prostate cancer imaging agent, Illuccix, and has a limited track record of revenue generation. Additionally, the company faces significant risks in terms of clinical and regulatory failures with its other potential radiopharmaceuticals. While the company has a promising pipeline, it may take several years for these programs to generate significant revenue, making it a risky investment.

TLX has been analyzed by 4 analysts, with a consensus rating of Strong Buy. 75% of analysts recommend a Strong Buy, 25% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Telix Pharmaceuticals Ltd and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Telix Pharmaceuticals Ltd (TLX) Forecast

Analysts have given TLX a Strong Buy based on their latest research and market trends.

According to 4 analysts, TLX has a Strong Buy consensus rating as of May 16, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $21.12, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $21.12, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Telix Pharmaceuticals Ltd (TLX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.